DHEA / Prasterone (Intrarosa): The Complete HRT Guide

Quick Reference Card

Overview / What Is DHEA / Prasterone?

The Basics

DHEA (dehydroepiandrosterone) is a hormone your body makes naturally, primarily in your adrenal glands. On its own, DHEA does not do much. Instead, it serves as a building block that your cells can use to make small amounts of other hormones, including estrogen and testosterone. Think of it as a raw ingredient that each tissue in your body can convert into whatever hormonal recipe it needs locally.

As you age, your body produces less and less DHEA. By the time menopause arrives, DHEA levels have typically dropped by about 60% from their peak. Since DHEA is the only remaining source of sex hormones in postmenopausal tissues (the ovaries have stopped producing estrogen directly), this decline can leave certain tissues, particularly the vaginal and vulvar areas, without the hormonal support they need.

Intrarosa is the FDA-approved form of prasterone (pharmaceutical-grade DHEA) delivered directly into the vagina as a small, bullet-shaped insert. Approved in November 2016, it was the first product to use DHEA as its active ingredient for treating moderate to severe painful intercourse caused by vulvar and vaginal atrophy due to menopause. What makes it distinct from vaginal estrogen creams, rings, or tablets is that it provides both estrogenic and androgenic support to vaginal tissues. This dual action may benefit not just vaginal lubrication and tissue health, but also nerve density and sensation in the vulvar area.

It is important to understand that Intrarosa is a prescription medication designed for local vaginal use only. It is not the same as over-the-counter DHEA supplements, which have not been evaluated by the FDA for treating any medical condition. Any decisions about using vaginal DHEA should be made in consultation with a qualified healthcare provider.

The Science

Prasterone (3-beta-hydroxyandrost-5-en-17-one; C19H28O2; molecular weight 288.424 g/mol) is the pharmaceutical name for dehydroepiandrosterone (DHEA), the most abundant circulating steroid hormone in women. DHEA and its sulfated conjugate DHEAS serve as the primary precursor reservoir for intracellular sex steroid biosynthesis in peripheral tissues through the process termed intracrinology [1][2].

Following the cessation of ovarian estrogen production at menopause, DHEA becomes the exclusive precursor for all estrogen and androgen synthesis in non-reproductive tissues. This represents a fundamental shift in sex steroid physiology: whereas premenopausal sex steroid production occurs primarily through endocrine mechanisms (ovarian secretion into the bloodstream), postmenopausal sex steroid availability depends entirely on intracrine mechanisms (local conversion within target cells) [1].

DHEA secretion declines progressively with age, beginning around age 30, with an approximately 60% reduction by the time of menopause [2]. There is no feedback mechanism to compensate for this decline, unlike the hypothalamic-pituitary-ovarian axis that regulates ovarian function. The rate of decline varies substantially between individuals, which partially explains why some postmenopausal women develop symptomatic vulvovaginal atrophy while others with higher endogenous DHEA activity remain asymptomatic [3].

Intrarosa (prasterone 6.5 mg vaginal inserts) received FDA approval on November 17, 2016 (NDA208470), following two pivotal 12-week randomized, double-blind, placebo-controlled clinical trials demonstrating efficacy for moderate to severe dyspareunia due to menopause [4]. It was manufactured by Endoceutics Inc. (Quebec City, Canada) and distributed by AMAG Pharmaceuticals. It remains the only FDA-approved intravaginal DHEA product.

Medical / Chemical Identity

Mechanism of Action

The Basics

To understand how Intrarosa works, imagine your vaginal tissue as a small kitchen that needs two key ingredients to stay healthy: estrogen and testosterone. Before menopause, your ovaries supplied most of the estrogen, and your adrenal glands provided DHEA, which individual cells could convert into whatever combination of estrogen and testosterone they needed. After menopause, the ovarian supply stops, and the adrenal DHEA supply has already been declining for years. Your vaginal tissue's kitchen is running low on ingredients.

Vaginal estrogen products (creams, rings, tablets) solve part of the problem by directly adding estrogen. But they only deliver one ingredient. Intrarosa takes a different approach: it delivers DHEA, the raw ingredient, directly to your vaginal tissue. Your vaginal cells then convert this DHEA into both estrogen and testosterone in exactly the proportions each cell needs. This process happens entirely within the cells themselves, which is why it is called intracrinology (meaning "within the cells").

The androgenic component (the testosterone pathway) appears to be particularly important for nerve health in the vulvar and vaginal area. Preclinical research suggests that androgens stimulate the growth of vaginal nerve endings, which may help explain why some women notice improvements in sensation and sexual response with DHEA that they did not experience with estrogen alone.

Because the conversion and action happen locally within the cells, and the resulting hormones are inactivated before they leave those cells, Intrarosa is designed to improve vaginal health without causing meaningful increases in hormone levels throughout the rest of the body.

The Science

The FDA-approved labeling states that prasterone is "an inactive endogenous steroid" that "is converted into active androgens and/or estrogens," and that "the mechanism of action of INTRAROSA in postmenopausal women with vulvar and vaginal atrophy is not fully established" [4].

The proposed mechanism centers on the concept of intracrinology as described by Labrie [1][2]. Intravaginally administered DHEA is taken up by vaginal and vulvar epithelial cells, where tissue-specific steroidogenic enzymes catalyze its conversion:

1. Estrogenic pathway: DHEA is converted by 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD) to androstenedione, which is then aromatized by CYP19 (aromatase) to estrone, and subsequently converted to estradiol by 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD) [1].
2. Androgenic pathway: Androstenedione is converted to testosterone by 17-beta-HSD, and testosterone is further converted to the potent androgen dihydrotestosterone (DHT) by 5-alpha-reductase [1].
3. Inactivation: The locally produced estradiol and testosterone are inactivated within the same cells by glucuronyl transferases and sulfotransferases, converting them to water-soluble glucuronide and sulfate conjugates that are released into the circulation in biologically inactive forms [2].

Preclinical evidence suggests that the androgenic component of intravaginal DHEA stimulates proliferation of vaginal nerve endings, which may account for improvements in sexual function domains (arousal, sensation, orgasm) beyond what vaginal estrogen alone provides [5]. This dual estrogenic-androgenic action within vaginal tissue is the primary mechanistic distinction between DHEA and vaginal estrogen products.

Importantly, the intracrine model predicts (and clinical pharmacokinetic data confirms) that serum concentrations of estradiol and testosterone remain within the normal postmenopausal range during Intrarosa treatment, suggesting that the local conversion and inactivation mechanism effectively limits systemic exposure [6].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

One of the most reassuring aspects of Intrarosa for many women is that it works locally. When you insert the vaginal suppository at bedtime, the hard fat base melts at body temperature and releases the DHEA into the vaginal tissue. Your vaginal cells absorb the DHEA and convert it into the estrogen and testosterone they need. Crucially, these hormones are then deactivated within the same cells before entering your bloodstream.

What does this mean in practical terms? Blood tests done during Intrarosa treatment show that your serum estradiol levels stay within the normal range for a postmenopausal woman (around 5 pg/mL). Your testosterone levels barely change. This is important because it means the medication is doing its job in the vagina without flooding the rest of your body with hormones.

The DHEA itself does rise in the blood after insertion (peaking at about 4.4 ng/mL), but since DHEA is biologically inactive on its own, this increase is not clinically meaningful. Your body handles the circulating DHEA exactly as it handles the DHEA your adrenal glands naturally produce.

One practical note: the hard fat base (Witepsol) that carries the DHEA will melt and can leak. This is a very common experience and does not mean the medication is not working. Inserting the suppository deeply and immediately lying down helps maximize absorption.

The Science

Following daily intravaginal administration of Intrarosa 6.5 mg for 7 days in postmenopausal women, the pharmacokinetic profile demonstrates local tissue targeting with limited systemic exposure [4]:

In the two pivotal 12-week efficacy trials, daily administration increased mean serum trough concentrations from baseline by 47% for prasterone, 21% for testosterone, and 19% for estradiol [4]. While these percentage increases appear substantial, the absolute values remain within the normal postmenopausal range.

Metabolism: Exogenous prasterone is metabolized identically to endogenous DHEA. Human steroidogenic enzymes, including hydroxysteroid dehydrogenases, 5-alpha-reductases, and aromatases, catalyze the intracellular conversion to androgens and estrogens. The tissue-specific enzyme profile in vaginal tissue favors production of both estradiol and testosterone, with subsequent intracellular inactivation via glucuronidation and sulfation [1][2].

Systemic comparison: The serum estradiol level achieved with Intrarosa (approximately 5 pg/mL) is comparable to other low-dose vaginal therapies: vaginal estradiol cream 0.01% (5.1 pg/mL), Estring vaginal ring (4.6 pg/mL), and vaginal estradiol inserts 10 mcg (5.5 pg/mL) [7].

Renal and hepatic impairment: The effects of renal and hepatic impairment on prasterone pharmacokinetics have not been studied [4].

Knowing the pharmacokinetics is the foundation. Seeing how your own body responds to your specific protocol turns that knowledge into actionable insight. Doserly correlates your dosing schedule with how you feel day to day, helping you and your provider identify whether your current route, timing, and dose are working optimally.

The app's analytics can surface patterns you might not notice on your own, like whether symptoms correlate with the end of a patch cycle or whether splitting an oral dose changes how you feel in the afternoon. Data like this makes dose adjustments more precise and less guesswork.

Research & Clinical Evidence

The Basics

The evidence for intravaginal DHEA comes primarily from a series of clinical trials conducted by the manufacturer, along with a 2026 meta-analysis that pooled data from multiple studies. Here is what the research tells us.

In two large, well-designed studies (randomized, double-blind, placebo-controlled), women who used Intrarosa daily for 12 weeks experienced meaningful improvements in painful intercourse compared to those using a placebo suppository. Their vaginal tissue also showed measurable changes: more healthy surface cells, fewer atrophic cells, and lower vaginal pH, all signs of tissue rejuvenation.

A 2026 meta-analysis combining data from six randomized controlled trials (1,611 women total) confirmed these findings, reporting significant improvements in both vaginal dryness and dyspareunia with a favorable safety profile [8].

One comparative review found that Intrarosa appeared to be at least as effective as vaginal conjugated estrogens (0.3 mg) or vaginal estradiol (10 mcg) for treating vulvovaginal atrophy symptoms [9]. This is a notable finding because it suggests the DHEA approach can match established estrogen therapies while providing the additional androgenic component.

An open-label study measuring sexual function more broadly found improvements across all domains: desire (+28%), arousal (+49%), lubrication (+115%), orgasm (+69%), and satisfaction (+41%) [5]. These broader sexual function improvements beyond simple pain reduction may reflect the androgenic component of DHEA's action on nerve density and sensation.

It is worth noting that the placebo response in vaginal atrophy trials tends to be substantial. In Trial 2, women receiving placebo suppositories (fat-based inserts without DHEA) also reported significant improvement in dyspareunia (a 1.06-point decrease on a 3-point scale), compared to a 1.42-point decrease with Intrarosa [4]. The moisturizing effect of the fat base itself likely contributes to this placebo benefit. Critical appraisal has noted that the outcome measures used in these trials were not validated and may not capture the complex psycho-sexual dimensions of GSM [10].

The Science

Pivotal Trial 1 (ERC-210): A 12-week randomized, double-blind, placebo-controlled trial enrolled 255 postmenopausal women (mean age 58.6 years) with moderate to severe dyspareunia. Results for the intention-to-treat population showed statistically significant improvements with Intrarosa versus placebo across all four co-primary endpoints [4]:

• Dyspareunia severity: -1.27 vs -0.87 (difference -0.40, p=0.0132)
• Superficial cells: +5.62% vs +0.91% (difference +4.71, p<0.0001)
• Parabasal cells: -47.40% vs -1.62% (difference -45.77, p<0.0001)
• Vaginal pH: -1.04 vs -0.21 (difference -0.83, p<0.0001)

Pivotal Trial 2 (ERC-231): A 12-week randomized, double-blind, placebo-controlled trial enrolled 558 postmenopausal women (mean age 59.5 years). Results confirmed efficacy [4]:

• Dyspareunia severity: -1.42 vs -1.06 (difference -0.35, p=0.0002)
• Superficial cells: +10.20% vs +1.75% (difference +8.46, p<0.0001)
• Parabasal cells: -41.51% vs -11.98% (difference -29.53, p<0.0001)
• Vaginal pH: -0.94 vs -0.27 (difference -0.67, p<0.0001)

Meta-analysis (2026): A systematic review and meta-analysis of six RCTs (n=1,611) found intravaginal DHEA significantly improved vaginal dryness (mean difference -0.23, 95% CI -0.35 to -0.11) and dyspareunia (mean difference -0.40, 95% CI -0.66 to -0.15) with low to moderate heterogeneity [8].

Comparative data: An indirect comparison review found daily 6.5 mg prasterone to be at least as efficacious as 0.3 mg conjugated estrogens or 10 mcg estradiol for VVA symptoms, with the advantage of no systemic estrogen exposure concerns [9].

Endometrial safety: A dedicated study found no effect of intravaginal prasterone on the endometrium in postmenopausal women, consistent with the intracrine mechanism that limits systemic sex steroid exposure [11]. However, the NAMS 2020 GSM position statement notes that endometrial safety has not been studied beyond 1 year [7].

Safety database: Four 12-week placebo-controlled trials plus one 52-week open-label trial comprise the safety database. No serious drug-related adverse events were identified [4].

Evidence & Effectiveness Matrix

The following matrix uses the 20 HRT symptom/outcome categories. Only categories with relevant data for intravaginal DHEA/prasterone are scored. Because Intrarosa is a local vaginal therapy (not a systemic HRT), many categories that apply to systemic hormone therapy do not apply here.

Categories not scored (insufficient data or not applicable for vaginal-only therapy):
Vasomotor Symptoms, Anxiety & Stress Response, Cognitive Function, Bone Health & Osteoporosis, Cardiovascular Health, Metabolic Health & Insulin Sensitivity, Body Composition & Weight, Joint & Musculoskeletal Health, Headache & Migraine, Thrombotic Risk, Menstrual & Reproductive, Other Physical Symptoms.

Benefits & Therapeutic Effects

The Basics

The primary benefit of Intrarosa is straightforward: it helps restore vaginal health in postmenopausal women experiencing painful intercourse and vaginal dryness. For women dealing with the distressing physical changes of vulvovaginal atrophy, which can affect everything from daily comfort to intimate relationships, this is not a small thing.

Clinical trials consistently show that Intrarosa improves several measurable markers of vaginal health. Vaginal pH drops back toward premenopausal levels. The proportion of healthy superficial vaginal cells increases significantly, while atrophic parabasal cells decrease. And, importantly, women report meaningful reductions in pain during sex.

Beyond the headline benefits, some women report improvements that the clinical trials did not specifically measure. These include improvement in recurrent urinary tract infections (a common consequence of vaginal atrophy), reduced urinary urgency, and better overall comfort in the vulvar area. Community reports also frequently mention improvement in clitoral sensation and sexual response, which may reflect the androgenic component of DHEA's action that vaginal estrogen alone does not provide.

One key advantage of Intrarosa compared to systemic HRT is its local action. Because DHEA is converted and inactivated within vaginal cells, serum hormone levels remain in the normal postmenopausal range. This local action profile means it does not require progestogen supplementation (even in women with an intact uterus), does not appear to affect the endometrium, and avoids the systemic side effects associated with oral or transdermal hormone therapy.

The Science

The evidence-based therapeutic effects of intravaginal prasterone include:

Vaginal tissue rejuvenation: Significant increases in vaginal superficial cells (maturation value) and decreases in parabasal cells across all trials. In Trial 2, superficial cells increased by 10.20% from baseline with Intrarosa vs 1.75% with placebo (p<0.0001), and parabasal cells decreased by 41.51% vs 11.98% (p<0.0001) [4].

Vaginal pH normalization: Reduction of vaginal pH toward premenopausal values (from approximately 6.3-6.5 at baseline to approximately 5.4 at 12 weeks), consistent with restoration of a lactobacillus-dominant vaginal microbiome [4].

Dyspareunia reduction: Clinically meaningful reduction in dyspareunia severity across both pivotal trials, confirmed by meta-analysis (mean difference -0.40, 95% CI -0.66 to -0.15) [8].

Sexual function improvement: The ERC-230 open-label study using the validated FSFI instrument demonstrated improvements in desire (+28%), arousal (+49%), lubrication (+115%), orgasm (+69%), satisfaction (+41%), and pain domains [5]. The magnitude of improvement in lubrication and orgasm domains exceeds what is typically reported with vaginal estrogen alone, potentially reflecting the androgenic component.

Proposed mechanism for sexual function benefits: Preclinical research suggests testosterone (derived from local DHEA conversion) stimulates vaginal nerve fiber density, which may explain improvements in arousal, sensation, and orgasm quality beyond what tissue moisturization alone would achieve [5].

No progestogen requirement: The NAMS 2020 GSM position statement confirms that when low-dose vaginal DHEA is administered, a progestogen is not indicated [7]. A dedicated study found no endometrial changes with intravaginal prasterone [11].

Risks, Side Effects & Safety

The Basics

The overall safety profile of Intrarosa is reassuring, particularly given its local action. In clinical trials spanning over 1,500 women, the only adverse reactions occurring more often than placebo were vaginal discharge and changes in Pap smear results. No serious drug-related adverse events were identified.

Common side effects:

• Vaginal discharge is the most frequently reported issue, occurring in about 6% of women in 12-week trials and 14% in the 52-week trial. This is largely the melted fat base (Witepsol) leaking out, not a sign that something is wrong. Many women find it manageable by inserting the suppository just before sleep and using a panty liner.
• Abnormal Pap smear results occurred in about 2% of women in the 52-week trial (10 cases of ASCUS and 1 LSIL). These are low-grade findings that typically require monitoring rather than intervention.

Side effects reported by users (not captured in clinical trial data):
Community reports identify additional experiences that did not appear as common adverse reactions in the clinical trials. These include hair thinning or loss, insomnia or feeling overstimulated (described as feeling "wired"), breast tenderness, acne, mood changes, headaches, and weight changes. These may reflect individual sensitivity to the androgenic metabolites of DHEA (testosterone and DHT), particularly in women who are more sensitive to androgenic effects. Healthcare providers can help evaluate whether symptoms are related to Intrarosa or other factors.

Breast cancer considerations:
This is an important area of uncertainty. Estrogen is a metabolite of prasterone, and the prescribing information states that use of exogenous estrogen is contraindicated in women with known or suspected history of breast cancer. Intrarosa has not been studied in women with a history of breast cancer. The NAMS 2020 GSM position statement notes that there are insufficient data to confirm the safety of vaginal DHEA in women with breast cancer, and management should be guided by the oncologist's recommendations [7].

Contraindications:

• Undiagnosed abnormal genital bleeding (must be evaluated before starting treatment)
• Known or suspected history of breast cancer (per labeling; clinical judgment applies)

What this medication does not increase risk of (based on current evidence):
Because Intrarosa works locally and does not significantly raise systemic hormone levels, the risks associated with systemic HRT (venous thromboembolism, stroke, cardiovascular events at the levels associated with oral estrogen) are not expected to apply. However, long-term safety data beyond 52 weeks remains limited.

The Science

Clinical trial safety data (N=1,522 prasterone-treated women across 5 trials):

The adverse reaction profile from four 12-week placebo-controlled trials (665 Intrarosa vs 464 placebo) and one 52-week open-label trial (521 women) identified only two treatment-emergent adverse reactions at >= 2% incidence [4]:

The Pap smear findings at 52 weeks comprised 10 cases of ASCUS and 1 case of LSIL, all low-grade [4]. No cases of high-grade squamous intraepithelial lesion or cervical cancer were reported.

Endometrial safety: A dedicated study demonstrated no effect of intravaginal prasterone on endometrial histology, supporting the intracrine model's prediction of negligible systemic estrogenic exposure to the uterus [11]. Progestogen co-administration is not required. However, the NAMS 2020 position statement notes that endometrial safety has not been studied in trials beyond 1 year [7].

Breast cancer risk: The prescribing information includes a warning regarding current or past breast cancer history, based on the fact that estrogen is a metabolite of prasterone. No clinical trials have enrolled women with a history of breast cancer. Serum estradiol levels with Intrarosa (approximately 5 pg/mL) are within the normal postmenopausal range and comparable to other low-dose vaginal therapies [7], but long-term breast tissue exposure data are not available.

Systemic safety context: Because Intrarosa maintains serum estradiol and testosterone within normal postmenopausal ranges, the systemic risks associated with oral or transdermal HRT (VTE at 18 additional events per 10,000 women per year with oral CEE per the WHI; breast cancer at 8 additional cases per 10,000 women per year with combined oral HRT) are not expected to apply to this local vaginal therapy. However, this distinction has not been confirmed in dedicated long-term safety studies comparing vaginal DHEA users to untreated controls for these endpoints.

Understanding your personal risk profile is not a one-time calculation; it evolves as your treatment progresses. Doserly helps you see the bigger picture by analyzing side effect patterns over time, showing whether issues are resolving, persisting, or emerging as your body adjusts to therapy.

The app's analytics can reveal connections between side effects and specific aspects of your protocol, like whether symptoms correlate with a particular point in your treatment cycle or a recent change. This kind of insight helps you and your provider make informed adjustments based on your actual experience, not just population-level averages.

Dosing & Treatment Protocols

The Basics

The dosing for Intrarosa is simple: one vaginal insert (6.5 mg of prasterone) placed into the vagina once daily at bedtime, using the provided applicator. There is only one dose strength available, and it does not need to be titrated up or down. This simplicity is one of the advantages of the product compared to some vaginal estrogen formulations that require a loading phase followed by maintenance dosing.

Consistency matters. Clinical trials used daily dosing throughout, and the benefits were measured after 12 weeks of continuous use. Many women notice some improvement within the first few weeks, but the full effect on tissue health, sensation, and comfort may take 2 to 3 months to develop. The 52-week trial demonstrated continued safety with long-term daily use.

Some women find that after their symptoms have resolved, they can reduce to less-than-daily use (every other day or a few times per week) while maintaining benefit. This is an off-label approach, but it is commonly discussed in patient communities and may be worth discussing with your prescriber, particularly given the cost of the medication.

No progestogen supplementation is required when using Intrarosa, even for women with an intact uterus. This is because the local intracrine mechanism does not produce systemic estrogen exposure sufficient to stimulate the endometrium.

Practical administration tips:

• Insert the suppository as the very last thing before lying down for sleep
• Insert as deeply as possible using the provided applicator
• The hard fat base will melt at body temperature and some leakage is normal; a panty liner may help
• Each applicator is single-use
• Store at room temperature (41-86F) or in the refrigerator; do not freeze

The Science

The dosing of intravaginal prasterone has been standardized through the clinical development program at a single fixed dose [4]:

The 6.5 mg dose was selected based on dose-finding studies (ERC-210 included a dose-comparison arm) and represents the concentration at which clinically meaningful improvements in VVA endpoints were achieved while maintaining serum sex steroid levels within normal postmenopausal ranges [4].

Comparison to vaginal estrogen dosing schedules:

• Vaginal estradiol cream: Typically daily for 1-2 weeks, then 1-3x/week
• Vaginal estradiol inserts (Imvexxy): Daily for 2 weeks, then twice weekly
• Vaginal estradiol ring (Estring): Continuous release, replaced every 90 days
• Vaginal DHEA (Intrarosa): Daily continuous (only FDA-approved regimen)

The daily dosing requirement for Intrarosa is frequently cited by patients as a disadvantage compared to twice-weekly vaginal estrogen alternatives.

Dosing protocols often change over the course of treatment, with adjustments based on individual response. Doserly maintains a complete history of every protocol change, giving you and your provider a clear picture of what has been tried and how each adjustment affected your symptoms.

The app's adherence analytics show your consistency patterns and can highlight whether missed doses or timing variations correlate with symptom changes. When your provider is considering a dose adjustment, having this data available makes the conversation more productive and the decision more informed.

What to Expect (Timeline)

Days 1-7: The hard fat base melts upon insertion, and some women experience vaginal discharge or leakage. This is the vehicle melting, not a side effect. A minority of women report initial cramping, a sense of overstimulation or difficulty sleeping, or mild irritation. These typically resolve within the first week or two as tissues adjust.

Weeks 2-4: Some women notice early improvements in vaginal comfort and moisture. Vaginal discharge from the fat base may decrease as absorption improves. Side effects like insomnia or feeling wired, if present, often begin to settle.

Months 1-3: This is when the clinical evidence shows meaningful change. Dyspareunia severity decreases significantly. Vaginal pH begins to normalize. Cytological changes (more superficial cells, fewer parabasal cells) become evident. Many women report that sex becomes comfortable again during this period. Some notice improvement in urinary symptoms as well.

Months 3-6: Full therapeutic effect for most women. Vaginal tissue health continues to improve. Women who initially experienced discharge may notice it decrease as tissue absorption improves. Sexual function domains (lubrication, arousal, orgasm) may continue to improve beyond the initial 3-month mark.

Ongoing maintenance: Annual review with healthcare provider is recommended. Some women continue daily use indefinitely; others, in consultation with their provider, trial reduced frequency. If treatment is stopped, symptoms typically recur as the underlying DHEA deficiency persists.

Timing Hypothesis & Window of Opportunity

The timing hypothesis, which suggests that systemic HRT initiated within 10 years of menopause onset or before age 60 may have a more favorable cardiovascular risk-benefit profile, is primarily relevant to systemic hormone therapy. Because Intrarosa is a local vaginal therapy that does not significantly alter systemic hormone levels, the timing hypothesis does not directly apply to initiation of this medication.

However, there is a related principle worth noting: vulvovaginal atrophy is a progressive condition. Unlike vasomotor symptoms, which may resolve over time, GSM symptoms tend to worsen without treatment and do not spontaneously improve. Earlier intervention may allow for better preservation of vaginal tissue health than waiting until atrophy is severe. Clinical trials enrolled women with moderate to severe symptoms; whether earlier treatment with milder symptoms would provide greater or more sustained benefit has not been specifically studied.

The NAMS 2020 GSM position statement emphasizes that GSM is underdiagnosed and undertreated, and that clinicians should proactively assess and manage these symptoms rather than waiting for patients to raise the topic [7].

Interactions & Compatibility

Drug-drug interactions:
The FDA prescribing information states that it is unlikely that other drugs taken orally or by injection will have an effect on prasterone used in the vagina [4]. Because Intrarosa acts locally with minimal systemic absorption, significant drug-drug interactions are not expected.

However, theoretical considerations include:

• Aromatase inhibitors (anastrozole, letrozole, exemestane): These medications block conversion of androgens to estrogens. Since DHEA's vaginal mechanism involves local aromatase activity, concurrent use could theoretically reduce the estrogenic component of Intrarosa's effect. Women on aromatase inhibitors for breast cancer should discuss any vaginal therapy with their oncologist.
• Tamoxifen and other SERMs: Intrarosa's local estrogen production could theoretically interact with selective estrogen receptor modulators. Again, oncologist guidance is essential.
• 5-alpha reductase inhibitors (finasteride, dutasteride): Could theoretically reduce the androgenic component of DHEA conversion. Not studied.

Supplement interactions:

• Oral DHEA supplements taken concurrently would add systemic DHEA exposure beyond what the vaginal insert provides. This combination has not been studied and could theoretically alter the local-action safety profile.
• No significant interactions expected with standard menopause-related supplements (calcium, vitamin D, black cohosh, omega-3).

Lifestyle factors:

• Smoking: No specific interaction data, but smoking worsens vaginal atrophy and may reduce treatment efficacy.
• The hard fat base is not compatible with latex condoms; non-latex alternatives should be used.

Related Doserly guides:

• Vaginal Estrogen Therapy (alternative treatment for GSM)
• Ospemifene (Osphena) (oral alternative for dyspareunia)
• Getting Started with HRT
• Genitourinary Syndrome of Menopause

Decision-Making Framework

Choosing the right treatment for vulvovaginal atrophy involves several considerations. Intrarosa is one of several effective options, and the best choice depends on your symptoms, preferences, medical history, and practical factors.

Who may be a good candidate for Intrarosa:

• Women with moderate to severe dyspareunia due to menopause
• Women who want both estrogenic and androgenic local support
• Women who have not responded adequately to vaginal estrogen alone
• Women who prefer a single-ingredient product with a simple dosing schedule (no loading phase)
• Women who value minimal systemic hormone exposure

Who may want to consider alternatives:

• Women who prefer less frequent dosing (twice-weekly vaginal estrogen options exist)
• Women who find daily vaginal insert use impractical
• Women sensitive to androgenic effects (hair thinning, acne)
• Women with a history of breast cancer (discuss all vaginal therapies with oncology team)
• Women for whom cost is a significant barrier (Intrarosa is often more expensive than generic vaginal estrogen)

Questions to discuss with your provider:

• Is my vaginal atrophy the primary cause of my symptoms, or could other conditions be contributing?
• Would I benefit from the androgenic component of DHEA, or would vaginal estrogen alone be sufficient?
• What are the cost implications, and is this medication covered by my insurance?
• How long should I try Intrarosa before deciding whether it is working?
• Can I use Intrarosa alongside other vaginal or systemic HRT?

Finding a specialist: The Menopause Society (formerly NAMS) maintains a directory of Certified Menopause Practitioners who have specific expertise in managing GSM and other menopause-related conditions. If your primary care provider is unfamiliar with vaginal DHEA, a menopause specialist may be a helpful resource.

Administration & Practical Guide

Step-by-step insertion:

1. Empty your bladder and wash your hands
2. Remove one applicator from the package and one insert from the blister strip
3. Pull back on the applicator plunger until it stops (this activates the applicator)
4. Carefully peel open the blister pack and remove the insert. If it falls on an unsanitary surface, use a new one
5. Place the flat end of the insert into the open end of the activated applicator
6. Choose a comfortable position: lying on your back with knees bent, or standing with one foot on a chair
7. Gently slide the applicator end into your vagina as far as it comfortably goes. Do not force it
8. Press the plunger with your index finger to release the insert
9. Remove and discard the applicator (single use only)
10. Remain lying down to minimize leakage

Practical tips from clinical experience and community reports:

• Timing: Insert as the absolute last activity before sleep. Getting up to use the bathroom after insertion allows the melted base to leak out.
• Leakage management: Some discharge of the melted fat base is normal and does not mean the medication failed. A panty liner at night can help. Leakage tends to decrease over time as tissue absorption improves.
• Staining: The fat base (Witepsol) can stain underwear and sheets. Dark-colored undergarments or sleeping on a towel may help during the initial weeks.
• Insertion depth: Insert as deeply as possible for best absorption and least leakage.
• Condom compatibility: The fat base is not compatible with latex condoms. Use non-latex (polyurethane or polyisoprene) condoms.
• Missed doses: Use the missed dose as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose. Do not use extra inserts to make up for missed doses.

This section provides general educational information and does not replace pharmacy instructions or prescriber guidance.

Monitoring & Lab Work

Before starting Intrarosa:

• Pelvic exam with assessment of vulvovaginal atrophy severity
• Rule out undiagnosed vaginal bleeding
• Breast cancer history screening
• Baseline Pap smear per standard screening guidelines
• Baseline assessment of symptoms (dyspareunia severity, vaginal dryness, urinary symptoms)

Initial follow-up (8-12 weeks):

• Symptom reassessment (clinical trials showed benefit at 12 weeks)
• Evaluation of side effects (discharge, any androgenic symptoms)
• Discussion of treatment response and whether to continue

Ongoing monitoring:

• Pap smear: Per standard screening guidelines. Be aware that Intrarosa may cause ASCUS findings (2.1% at 52 weeks in trials); these should be managed per standard Pap smear guidelines rather than automatically attributed to the medication
• Mammography: Per standard screening guidelines; no additional screening required specifically due to Intrarosa use based on current evidence
• Endometrial monitoring: Routine endometrial monitoring is not required. Transvaginal ultrasound should be performed if abnormal vaginal bleeding occurs
• Hormone levels: Routine serum hormone level testing is not necessary during Intrarosa use, as levels remain within normal postmenopausal ranges

Annual review checklist:

• Symptom control assessment
• Side effect evaluation
• Discussion of continued need for treatment
• Review of any new medical conditions (particularly breast cancer risk factors)
• Standard preventive screening (Pap, mammogram, bone density per guidelines)

Complementary Approaches & Lifestyle

For women with vulvovaginal atrophy, several complementary strategies can enhance the benefits of Intrarosa or serve as first-line approaches for milder symptoms:

Vaginal moisturizers: Over-the-counter products (Replens, Revaree hyaluronic acid, K-Y Liquibeads) applied regularly (not just before sex) help maintain vaginal moisture between Intrarosa doses. The NAMS 2020 position statement recommends these as first-line for mild GSM symptoms [7].

Lubricants: Water-based or silicone-based lubricants used during sexual activity can supplement Intrarosa's effects. Avoid products with glycerin, warming agents, or parabens, which may irritate atrophic tissue.

Pelvic floor therapy: A pelvic floor physical therapist can address muscle tension, pain patterns, and urinary symptoms that often accompany vaginal atrophy. Pelvic floor therapy is particularly helpful for women with significant dyspareunia.

Regular sexual activity or vaginal dilator use: Maintaining vaginal blood flow through regular use (sexual activity, self-stimulation, or vaginal dilators) supports tissue health and complements hormonal therapy.

Exercise: Regular physical activity supports overall wellbeing and may benefit pelvic floor health. Weight-bearing and resistance exercise is particularly important during menopause for bone and metabolic health.

Vitamin D and calcium: Important for overall menopause health, though not directly related to GSM treatment. See Menopause Nutrition & Lifestyle.

Non-hormonal prescription alternatives: For women who cannot use hormonal vaginal therapies, ospemifene (Osphena) is an oral selective estrogen receptor modulator FDA-approved for dyspareunia. See Ospemifene (Osphena).

Stopping HRT / Discontinuation

Because Intrarosa treats the underlying tissue changes of vulvovaginal atrophy (which are progressive and do not resolve spontaneously), discontinuation will generally lead to symptom recurrence. The timeline varies between individuals, but most women will notice a gradual return of dryness, discomfort, and atrophic changes within weeks to months of stopping.

When to consider stopping:

• Resolution of symptoms with desire to trial a treatment break
• Unacceptable side effects (hair loss, mood changes, cost)
• New diagnosis of breast cancer (discuss with oncology team)
• Preference to switch to an alternative therapy (vaginal estrogen, ospemifene)

Tapering vs abrupt cessation:
There is no established tapering protocol for Intrarosa. Because it is a local therapy without systemic hormone dependency, abrupt cessation does not cause withdrawal symptoms in the way that stopping systemic HRT might. Some women choose to gradually reduce frequency (daily to every other day to twice weekly) before stopping, which may slow the return of symptoms and help assess the minimum effective frequency.

Monitoring during discontinuation:

• Symptom diary to track the return of vaginal dryness or dyspareunia
• Follow up with healthcare provider if symptoms return significantly

Restarting treatment:
Intrarosa can be restarted at any time if symptoms return. There is no contraindication to restarting after a break.

Special Populations & Situations

Breast Cancer Survivors

This is the most clinically significant special population for Intrarosa. Estrogen is a metabolite of prasterone, and the prescribing information warns about use in women with a current or past history of breast cancer. Intrarosa has not been studied in women with breast cancer. The NAMS 2020 GSM position statement states there are insufficient data to confirm the safety of vaginal DHEA in women with breast cancer [7].

Women taking aromatase inhibitors, tamoxifen, or other hormonal therapy for breast cancer should not use Intrarosa without explicit guidance from their oncology team. Even though serum estradiol levels remain in the normal postmenopausal range, the theoretical concern about local estrogen production in tissue adjacent to vulvar/vaginal areas remains.

Non-hormonal alternatives for breast cancer survivors with GSM include: vaginal moisturizers, lubricants, pelvic floor therapy, vaginal dilators, and ospemifene (though ospemifene also has estrogenic activity and requires oncologist guidance).

Premature Ovarian Insufficiency (POI)

Women with POI typically require systemic HRT for cardiovascular and bone protection, not just vaginal therapy. Intrarosa could theoretically be used as an adjunct for persistent GSM symptoms not fully addressed by systemic HRT, but this use case is not specifically studied. See Premature Ovarian Insufficiency.

Surgical Menopause

Women who experience abrupt menopause following bilateral oophorectomy may develop more severe and rapid-onset vaginal atrophy. Intrarosa could be used as a stand-alone treatment for GSM or as an adjunct to systemic HRT. Some community reports suggest particular benefit in post-surgical women who experience combined estrogenic and androgenic deficiency symptoms. See Surgical Menopause.

Women on Systemic HRT with Persistent GSM

Some women on systemic estrogen therapy continue to experience vaginal symptoms. Adding Intrarosa to systemic HRT is practiced clinically but has not been specifically studied in controlled trials. The combination may provide additional local androgenic benefit.

Women with Fibroids

The European Medicines Agency and the Electronic Medicines Compendium in the UK list fibroids in the warnings for Intrarosa. Women in the clinical trials who had fibroids were excluded. Women with known fibroids should discuss potential risks with their healthcare provider.

Regulatory, Insurance & International

United States (FDA):

• FDA-approved November 17, 2016 (NDA208470)
• Indication: Moderate to severe dyspareunia, a symptom of VVA, due to menopause
• Prescription required; classified as miscellaneous sex hormones
• Insurance coverage is inconsistent. Many plans require prior authorization or do not cover Intrarosa. Out-of-pocket costs commonly range from $84-300+/month. The manufacturer has offered savings programs and coupons.
• Important distinction: FDA-approved Intrarosa is different from OTC DHEA supplements. The efficacy and safety of OTC DHEA supplements have not been established for treating any medical condition.

European Union (EMA):

• EMA approved January 2018 for treatment of VVA in postmenopausal women with moderate to severe symptoms
• Brand name: Intrarosa
• Available in some EU member states

United Kingdom (MHRA):

• Licensed in the UK in 2018
• Availability has been inconsistent; supply shortages have been reported by community members
• Not routinely available on NHS; may require private prescription

Canada (Health Canada):

• Available as Intrarosa
• Coverage varies by province

Australia (TGA):

• Not currently marketed in Australia

Compounding considerations:
Some women and providers use compounded vaginal DHEA preparations as a lower-cost alternative to Intrarosa. Compounded preparations do not undergo FDA review for safety, efficacy, or quality. The concentration, purity, and pharmacokinetics of compounded DHEA may differ from FDA-approved Intrarosa. The decision to use compounded preparations should involve discussion of these trade-offs with a healthcare provider.

OTC DHEA supplements used vaginally:
This practice (inserting OTC DHEA tablets vaginally) is widely discussed in patient communities but is an off-label, unregulated approach. OTC supplements are not required to meet pharmaceutical-grade purity, potency, or dissolution standards. Healthcare providers cannot endorse this practice but should be aware that patients may be using it.

Frequently Asked Questions

Q: How is Intrarosa different from vaginal estrogen?
A: Vaginal estrogen products deliver estrogen directly to vaginal tissue. Intrarosa delivers DHEA, which vaginal cells convert into both estrogen and testosterone locally. This dual hormonal action may provide benefits for nerve health, sensation, and sexual function beyond what estrogen alone offers. However, Intrarosa requires daily use, while some vaginal estrogen products can be used just twice weekly after an initial loading period.

Q: Will Intrarosa help with hot flashes or other menopause symptoms?
A: No. Intrarosa works locally in the vagina and does not significantly raise systemic hormone levels. It is specifically designed for vaginal symptoms (pain during sex, dryness, atrophy) and will not address hot flashes, night sweats, mood changes, or other systemic menopause symptoms. Systemic HRT is needed for those symptoms.

Q: Can I use Intrarosa if I have had breast cancer?
A: This is a complex question that requires individual clinical assessment. The prescribing information warns about use in women with breast cancer because estrogen is a metabolite of DHEA. Intrarosa has not been studied in women with breast cancer. Discuss with your oncologist, who can weigh the risks and benefits for your specific situation.

Q: Why is there so much discharge/leakage?
A: The DHEA is suspended in a hard fat base (Witepsol) that melts at body temperature to release the medication. Some of this melted fat inevitably leaks out. This is normal and does not mean the medication is not working. Inserting deeply and staying lying down helps maximize absorption.

Q: Can I just use OTC DHEA supplements instead?
A: OTC DHEA supplements have not been evaluated by the FDA for treating vaginal atrophy. They are not manufactured to pharmaceutical-grade standards for purity, potency, or dissolution. While some women do use OTC DHEA vaginally (a practice discussed in patient communities), this is an unregulated approach with unknown consistency. Discuss with your healthcare provider.

Q: How long does it take to work?
A: Clinical trials measured outcomes at 12 weeks. Many women notice some improvement within the first few weeks, but full benefit typically develops over 2-3 months. Patience and consistent daily use during this period are important.

Q: Do I need to take progesterone with Intrarosa?
A: No. Because Intrarosa works locally and does not significantly stimulate the endometrium, progestogen supplementation is not required, even for women with an intact uterus.

Q: Will Intrarosa increase my sex drive?
A: The evidence is mixed. Intrarosa reliably improves physical aspects of sexual function (lubrication, reduced pain, tissue health). Some women report improved arousal and orgasm quality, possibly related to local testosterone effects on nerve density. However, central sexual desire (libido) improvement is inconsistent. If low libido is your primary concern, discuss testosterone therapy options with your provider.

Q: Can I use Intrarosa alongside vaginal estrogen?
A: This combination is used in clinical practice (for example, Intrarosa on some nights and vaginal estrogen on others) but has not been studied in controlled trials. Discuss with your healthcare provider.

Q: Is it safe for long-term use?
A: The longest clinical trial was 52 weeks, and no serious safety concerns emerged. Many women use it for years. Long-term safety data beyond the clinical trial period comes from post-marketing surveillance and is reassuring, but formal long-term studies are lacking.

Q: Why is it so expensive?
A: Intrarosa is a branded pharmaceutical product protected by patents. Generic versions are not yet available. Insurance coverage varies widely. The manufacturer has offered savings programs. Some women and providers use compounded alternatives, though these do not undergo FDA review.

Myth vs. Fact

Myth: DHEA supplements from the health food store are the same as Intrarosa.
Fact: OTC DHEA supplements are dietary supplements, not pharmaceuticals. They are not required to meet FDA standards for purity, potency, dissolution, or consistency. Intrarosa is a pharmaceutical-grade product that has been tested in clinical trials with over 1,500 women. The active ingredient is the same molecule, but the formulation, quality control, and evidence base are fundamentally different.

Myth: Intrarosa will increase my risk of blood clots and stroke like oral HRT.
Fact: The VTE and stroke risks associated with systemic HRT are driven by oral estrogen's first-pass effect on the liver, which increases production of clotting factors. Intrarosa works locally in the vagina and does not significantly raise systemic estrogen levels (serum estradiol remains approximately 5 pg/mL, within normal postmenopausal range). The systemic risks of oral HRT do not apply to this local therapy based on current evidence.

Myth: Vaginal DHEA is unsafe because it contains hormones.
Fact: DHEA itself is an inactive precursor, not an active hormone. It is converted to small amounts of estrogen and testosterone within vaginal cells, where these hormones act locally and are then inactivated before entering the bloodstream. This intracrine mechanism means the "hormonal" effect is contained within the target tissue. Serum hormone levels remain comparable to those seen with other low-dose vaginal therapies and within normal postmenopausal ranges [4][7].

Myth: If vaginal estrogen did not work for me, DHEA will not work either.
Fact: Intrarosa provides both estrogenic AND androgenic support to vaginal tissue. Some women who have not responded adequately to vaginal estrogen alone report improvement with vaginal DHEA, possibly because the androgenic component (local testosterone) contributes to nerve fiber density and tissue health in ways that estrogen alone does not [5]. Individual responses vary, and a trial of 2-3 months is recommended before assessing effectiveness.

Myth: The messy discharge means the medication is not being absorbed.
Fact: The discharge is the melted fat base (Witepsol) that carries the DHEA. The DHEA is absorbed into the vaginal tissue as the base melts. Some fat base leaking out is inevitable and does not indicate treatment failure. Clinical trial participants experienced the same leakage and still showed significant improvements in all measured outcomes.

Myth: You should stop Intrarosa after a year because long-term use is not safe.
Fact: The 52-week clinical trial showed continued safety with ongoing use, and many women have used it for several years. The NAMS 2020 position statement does note that endometrial safety has not been studied beyond 1 year in clinical trials [7], but this is a data gap, not evidence of harm. Ongoing treatment decisions should be made with your healthcare provider based on individual risk-benefit assessment.

Myth: Intrarosa causes breast cancer.
Fact: There is no evidence that Intrarosa causes breast cancer. The prescribing information warns about use in women with existing breast cancer because estrogen is a metabolite of DHEA, and estrogen can stimulate hormone-receptor-positive breast cancer growth. However, the serum estradiol levels achieved with Intrarosa (approximately 5 pg/mL) are within the normal postmenopausal range. Long-term breast cancer incidence data specifically for vaginal DHEA users are not yet available.

Myth: Intrarosa is just a money grab; DHEA is cheap and could be sold over the counter for this purpose.
Fact: While DHEA as a molecule is inexpensive, the development of a pharmaceutical-grade vaginal formulation with consistent dissolution and delivery properties, supported by multiple randomized controlled trials with over 1,500 women, represents significant investment. OTC DHEA supplements have not undergone this level of testing for vaginal use and may vary in quality. That said, the high price of Intrarosa is a legitimate concern that affects treatment access, and lower-cost alternatives (compounded preparations, generic vaginal estrogen) are worth discussing with a healthcare provider.

Sources & References

Clinical Guidelines

1. Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues. Menopause. 2019;26(2):220-224.
2. Labrie F, Belanger A, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24:702-712.
3. Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause. 2011;18(1):30-43.
4. INTRAROSA (prasterone) vaginal inserts prescribing information. AMAG Pharmaceuticals, Inc. Revised February 2018. NDA208470.
5. Bouchard C, Labrie F, Derogatis L, et al. Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. Horm Mol Biol Clin Investig. 2016;25(3):181-190.
6. Labrie F, Martel C, Berube R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol. 2013;138:359-367.
7. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.

Landmark Trials & Systematic Reviews

1. Intravaginal dehydroepiandrosterone for the treatment of vulvovaginal atrophy in postmenopausal women: a systematic review and meta-analysis. JAMA Netw Open. 2026 (PMID: 41589851).
2. Labrie F, Archer DF, Koltun W, et al. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens, and 10mcg estradiol on vulvovaginal atrophy symptoms. J Steroid Biochem Mol Biol. 2017;170:223-228.
3. Kearley-Shiers K. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the menopause: Is the evidence sufficient? Post Reprod Health. 2023;29(2):85-91.

Observational Studies

1. Portman DJ, Labrie F, Archer DF, et al. Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause. 2015;22(12):1289-1295.

Government/Institutional Sources

1. FDA News Release: FDA approves Intrarosa for postmenopausal women experiencing pain during sex. November 17, 2016.
2. Labrie F, Archer DF, Bouchard C, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243-256.
3. Phillips N, Bachmann G. Genitourinary syndrome of menopause (GSM): the role of intravaginal DHEA (prasterone). Curr Sex Health Rep. 2018;10:109-113.

Related Guides & Cross-Links

Same Category (Androgens, Women's Context)

• Testosterone Undecanoate (Investigational)

Related Treatment Options

• Vaginal Estrogen Therapy (alternative local GSM treatment)
• Ospemifene (Osphena) (oral non-estrogen alternative for dyspareunia)
• Testosterone Therapy for Women (systemic testosterone for libido)
• Getting Started with HRT

Related Conditions

• Genitourinary Syndrome of Menopause
• Menopause
• Surgical Menopause
• Sexual Health During Menopause

Complementary Approaches

• Menopause Nutrition & Lifestyle
• Non-Hormonal Menopause Treatments